Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828648 | 0.72 | MAPK14 (0.36) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL827829 | 0.72 | MAPK14 (0.36) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL23021737 | 0.63 | RECQL (0.48) | MAPT | |
| SCHEMBL827781 | 0.63 | ROCK2 (0.37) | SYK | |
| SCHEMBL9771729 | 0.62 | KDM4D (0.43) | — | |
| SCHEMBL828647 | 0.61 | MAPK14 (0.34) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10444896 | 0.60 | NOS2 (0.52) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL3781770 | 0.60 | MAPK1 (0.33) | P2RX7 | |
| SCHEMBL3434426 | 0.60 | MAPK1 (0.33) | P2RX7 | |
| SCHEMBL14076715 | 0.60 | NOS2 (0.42) | MAPK13MAPK12MAPK11MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | MAPK13 2885/4885MAPK12 2358/4885MAPK11 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.